Publication | Closed Access

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

Rheumatoid DisorderRheumatologyRheumatic DiseasesInflammatory Rheumatic DiseaseHead-to-head ComparisonDermatologyMedicineRandomised Exxelerate StudyOrthopaedic SurgeryRheumatoid Arthritis